Preliminary research shows Anplag could be repurposed as a heart failure treatment at a lower cost.
Formulary Watch
Latest News
All News
Advertisement
Now called Comirnaty, the vaccine is approved for those 16 years and older.
The FDA has set a PDUFA date of December 23, 2021.
Generics of Chantix, Durezol, Eliquis, and injection potassium/sodium are approved while generics of Tegretol and Levophed are launched.
The therapy is the first approved for patients with tumors associated with von Hippel-Lindau disease.
The report found that mavacamten offers benefits but was above the threshold of $150,000 per quality-adjusted life-years.
These results can be used to inform health care decisions, but investigators caution there hasn’t been head-to-head trials of the two therapies.
Including patients in the decision-making process, the authors said, is an important component of patient-centered health care.
The monoclonal antibody had been given an emergency use authorization to treat COVID-19, but the recent spike in cases is driving a shortage in supply.
Advertisement
The move, effective July 15, was the result of a generic now being available.
A total of 16 lots have been recalled.
The therapy is expected to be available by early September.
Effective January 2023, the organization will switch from Express Scripts to CVS Caremark.
This vaccine protects against tick-borne encephalitis in people over the age of 1 year.
The multiple myeloma therapy now has a permanent J code under Medicare Part B.
Trials result show that Lyumjev compares favorably to Humalog.
All stakeholders together incur about $93.3 billion in costs for implementing, contesting, and navigating drug utilization management.
This is the first approval of generic version of Chantix, and it comes just weeks after a recall of the brand-name drug.
The potassium-lowering agent was associated with a 20% relative reduction in costs related to outpatient, inpatient, and emergency department visits.
Four products on the preferred list this year will be excluded next year.
The VA recommends against offering this agent to patients with Alzheimer’s dementia, mild or otherwise.
The program and proposed integrations could produce $15 million in savings annually.
The decision follows an advisory committee recommendation not to approve because of safety issues.
Libtayo also reduced the risk of death by 29% compared with chemotherapy alone.
Advertisement
Advertisement